<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04266522</url>
  </required_header>
  <id_info>
    <org_study_id>2019-104</org_study_id>
    <nct_id>NCT04266522</nct_id>
  </id_info>
  <brief_title>Medical Physics Direct Patient Care for the Improvement of Patient Understanding of Care</brief_title>
  <official_title>Medical Physics Direct Patient Care Initiative - Communication Intervention Study Protocol</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Barbara Ann Karmanos Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Barbara Ann Karmanos Cancer Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial studies how well medical physics direct patient care works in improving
      patients' understanding of their cancer treatment. Providing direct physicist-patient
      interactions and answering patients' questions about their cancer treatment may help patients
      to understand the care and therefore reduce anxiety and distress during treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVE:

      I. To evaluate whether the Medical Physics Direct Patient Care Initiative (MPDPCI) improves
      anxiety/distress.

      SECONDARY OBJECTIVE:

      II. To assess whether the MPDPCI improves patient treatment adherence and overall
      satisfaction.

      OUTLINE: Patients are randomized to 1 of 2 arms.

      ARM I: Patients receive printed materials describing the technical aspects of their
      treatment.

      ARM II: Patients receive printed materials as in Arm I. Patients also receive a minimum of 2
      direct physicist interactions to describe the technical aspects of their treatment either
      immediately prior to or immediately after treatment simulation.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 16, 2020</start_date>
  <completion_date type="Anticipated">June 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Anxiety</measure>
    <time_frame>4 months</time_frame>
    <description>Will be assessed using linear mixed-effects models. These objectives will be evaluated based on the difference between groups across three time points (i.e., group-effect) using the baseline corrected measurements. Each patient will be considered as random-effects along with the repeated measurements at three time points. The repeated measurements at three time points will be handled by autocorrelated residuals within groups.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Distress</measure>
    <time_frame>4 months</time_frame>
    <description>Will be assessed using linear mixed-effects models. These objectives will be evaluated based on the difference between groups across three time points (i.e., group-effect) using the baseline corrected measurements. Each patient will be considered as random-effects along with the repeated measurements at three time points. The repeated measurements at three time points will be handled by autocorrelated residuals within groups.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient treatment adherence</measure>
    <time_frame>4 months</time_frame>
    <description>Will be assessed using 2-sided unpaired t-test.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">64</enrollment>
  <condition>Malignant Neoplasm</condition>
  <arm_group>
    <arm_group_label>Arm I (printed materials)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive printed materials describing the technical aspects of their treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II (printed materials, physicist interaction)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive printed materials as in Arm I. Patients also receive a minimum of 2 direct physicist interactions to describe the technical aspects of their treatment either immediately prior to or immediately after treatment simulation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Informational Intervention</intervention_name>
    <description>Receive printed materials</description>
    <arm_group_label>Arm I (printed materials)</arm_group_label>
    <arm_group_label>Arm II (printed materials, physicist interaction)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Counseling</intervention_name>
    <description>Receive direct physicist interactions to describe the technical aspects of the treatment</description>
    <arm_group_label>Arm II (printed materials, physicist interaction)</arm_group_label>
    <other_name>counseling, Counseling Intervention</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Questionnaire Administration</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>Arm I (printed materials)</arm_group_label>
    <arm_group_label>Arm II (printed materials, physicist interaction)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Medical physicists will be eligible if they care for patients within the Gershenson
             Radiation Oncology Center within the Karmanos Cancer Institute and have completed the
             patient communication training

          -  Are able to read and write in English

          -  Are scheduled for curative radiation therapy at the Gershenson Radiation Oncology
             Center

        Exclusion Criteria:

          -  NONE
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jay Burmeister, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Barbara Ann Karmanos Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jay Burmeister, PhD</last_name>
    <phone>(313) 576-9617</phone>
    <email>burmeist@karmanos.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Barbara Ann Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jay Burmeister, PhD</last_name>
      <phone>313-576-9617</phone>
      <email>burmeist@karmanos.org</email>
    </contact>
    <investigator>
      <last_name>Lauren Hamel, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Geoff Baran, M.S.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Brian Loughery, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kathryn Masi, M.S.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michael Dominello, D.O.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Harold Kim, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mara Jelich, M.S.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pam Laszewski, B.S.N.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michael Joiner, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>February 10, 2020</study_first_submitted>
  <study_first_submitted_qc>February 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 12, 2020</study_first_posted>
  <last_update_submitted>March 11, 2020</last_update_submitted>
  <last_update_submitted_qc>March 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Barbara Ann Karmanos Cancer Institute</investigator_affiliation>
    <investigator_full_name>Jay Burmeister</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

